For questions about BMS medicines during this time,
please call 1-800-721-8909.

pJIA is a type of arthritis that affects children and teens

It may have been a long road to get to your child’s diagnosis of polyarticular juvenile idiopathic arthritis because of the slow, progressive nature of
the disease.

Some of the joint symptoms you may be familiar with include:

  • Pain
  • Stiffness
  • Swelling

For some parents, having a name for your child’s condition can bring a sense of relief. Because the sooner you know what is causing your child’s pain, the sooner you can begin to treat it.

ORENCIA was proven to reduce the symptoms of pJIA

This clinical study compared ORENCIA intravenous (IV) infusion against a placebo IV infusion in children who weren’t helped by
disease-modifying antirheumatic drugs (DMARDs). 60 children were in the ORENCIA group and 62 were in the placebo group.

After 6 months of treatment:

Reduced flares

20% of children experienced a flare with ORENCIA compared with 53% of children taking placebo.

What was the purpose of this study?

This study looked at the results and safety of ORENCIA IV compared with placebo IV after 6 months.

Characteristics that children needed to have in order to be included in this study:

  • 6 to 17 years old
  • Living with moderately to severely active pJIA
  • Not helped by one or more DMARD

What was compared in this study?

190 children were initially in this study. After 4 months, children who had reduced signs and symptoms were then split into 2 groups to help compare their responses to treatment. One group of 60 children received ORENCIA, and the other group of 62 children
received placebo.

This clinical study looked at ORENCIA self-injection in children who weren’t helped by disease-modifying antirheumatic drugs (DMARDs).
205 children were part of this study.

After 4 months of treatment:

Reduced symptoms

Results in this study were similar to the results for ORENCIA IV.

What was the purpose of this study?

This study looked at the results and safety of ORENCIA self-injection.

Characteristics that children needed to have in order to be included in this study:

  • 2 to 17 years old
  • Living with active pJIA
  • Not helped by one or more DMARD

Ask your doctor if ORENCIA may be right for your child.

Get financial support throughout treatment with ORENCIA On CallTM